OXGN Key Stats
- Nasdaq stocks posting largest percentage increases May 20
- OXIGENE INC Files SEC form 10-Q, Quarterly Report May 9
- OXiGENE Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 6
- OXiGENE Reports First Quarter 2013 Financial Results GlobeNewswire May 6
- OXIGENE INC Files SEC form 8-K, Results of Operations and Financial Condition May 6
- Q1 2013 OXiGENE, Inc. Earnings Release - After Market Close May 6
- OXiGENE's Oncology Drugs Have Run Their Course May 1
- OXIGENE (OXGN) Files 4.3M Common Shelf for Holders Street Insider Apr 25
- Oxigene files to sell 4.3M shares of common stock for holders Apr 24
- OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cance... Apr 24
OXGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). OxiGene is down 68.30% over the last year vs S&P 500 Total Return up 27.50%, Acorda Therapeutics up 40.91%, and ImmunoCellular Therapeutics down 10.18%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for OXGN
Pro Report PDF for OXGN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download OXGN Pro Report PDF
Pro Strategies Featuring OXGN
Did OxiGene make it into our Pro Portfolio Strategies?